A

Amgen

Makes biotech medicines for serious illnesses

Director of U.S. Consumer Marketing - Sjögren’s Disease

Full-TimePosted on 10/23/2026
$184.3k - $249.4k+ Discretionary annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's, MBA, PhD
Deerfield, IL, USA
HybridFlex commuter/hybrid work arrangement.
Growth & MarketingProduct Marketing
H1B Sponsorship Available

About the job

Requirements
  • A doctorate degree and 4 years of marketing experience, or a master's degree and 8 years of marketing or commercial experience, or a bachelor's degree and 10 years of marketing or commercial experience.
  • Demonstrated success leading pharmaceutical or biotechnology product launches.
  • Experience launching first-in-class therapies and building markets in areas of high unmet need.
  • Demonstrated success leading through ambiguity and rapidly evolving competitive landscapes.
  • Experience building commercial organizations and leading teams through pre-launch and launch.
  • Significant U.S. marketing experience with integrated commercial strategy development.
  • Experience hiring, coaching, and developing high-performing teams.
  • Experience in autoimmune disease, immunology, rheumatology, or rare disease.
  • Experience partnering with Medical Affairs, Market Access, Sales, and Global Marketing.
  • Strong strategic thinking and ability to translate insights into impactful commercial plans.
Responsibilities
  • Set the U.S. consumer strategy and launch plan, translating patient and caregiver needs into priorities, measurable objectives, and an integrated omnichannel approach.
  • Build and lead a high-performing consumer marketing team; coach and develop talent, set clear accountability, and foster an inclusive, collaborative culture.
  • Lead insight-driven campaigns and creative across video, digital, social, website, email/CRM, point of care, and media to increase disease awareness and encourage informed patient action.
  • Develop a connected patient journey aligning consumer communications, education, engagement, and appropriate onboarding and support touchpoints.
  • Lead presence at society and advocacy meetings; support field-based marketing in executing local and digital patient and family educational events.
  • Maintain understanding of the competitive landscape, customer insights, and market dynamics to inform commercial strategy and identify growth opportunities.
  • Partner with Patient Advocacy, patient leaders, and relevant organizations to inform strategy, build trusted relationships, and support appropriate educational and engagement programs.
  • Partner with HCP Marketing and cross-functional teams to connect patient and HCP strategies and deliver a coordinated launch experience.
  • Use market research, audience insights, and performance data to optimize messaging, creative, channel mix, and investment; track consumer engagement and campaign effectiveness.
  • Lead agency and media partners, manage budgets and promotional investments, and monitor performance to maximize launch-resource impact and efficiency.
  • Maintain understanding of patient needs, market dynamics, and the evolving competitive landscape; translate insights into recommendations and growth opportunities.
  • Model Amgen Values and foster collaboration, innovation, accountability, and high performance across the consumer team and broader launch organization.
Desired Qualifications
  • An MBA is preferred.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.